https://www.selleckchem.com/pr....oducts/i-bet-762.htm
4% vs. 77.0%, p less then 0.0001). LSRCC and LMAC patients exhibited median overall survival (OS) duration of 8 and 18 months (p less then 0.0001), respectively, although these differences were not significant after adjusting for confounding variables. Independent factors associated with a favorable patient prognosis included a primary site in the middle or lower lung lobe, underwent surgery, and underwent chemotherapy. However, age ≥80 years, higher grade, distant summary stage disease, and T4 stage disease were linked to poor progno
Like
Comment
Share
